A Study of CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
Latest Information Update: 17 May 2024
Price :
$35 *
At a glance
- Drugs Anti CD19 BAFF chimeric antigen receptor T cell therapy Yake Biotechnology (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 13 May 2024 Planned End Date changed from 15 Apr 2027 to 30 May 2027.
- 13 May 2024 Planned primary completion date changed from 15 Apr 2027 to 30 May 2027.
- 13 May 2024 Status changed from not yet recruiting to recruiting.